Informace o publikaci

Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer

Autoři

SLABÝ Ondřej SVOBODA Marek FABIAN Pavel ŠMERDOVÁ Tamara KNOFLÍČKOVÁ Dana BEDNAŘÍKOVÁ Markéta NENUTIL Rudolf VYZULA Rostislav

Rok publikování 2008
Druh Článek v odborném periodiku
Časopis / Zdroj Oncology
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstract&ArtikelNr=113489&Ausgabe=234514&ProduktNr=223857
Obor Onkologie a hematologie
Klíčová slova microRNA; colorectal cancer; pathogenesis
Popis Objectives: Development and metastases of colorectal cancer (CRC) are characterized by multiple genetic alterations. MicroRNAs (miRNAs) are endogenously expressed regulatory noncoding RNAs. Previous, mainly preclinical studies showed altered expression levels of several miRNAs in CRC. Methods: In our study, the expression levels of miR-21, miR-31, miR-143 and miR-145 in 29 primary colorectal carcinomas and 6 non-tumor adjacent tissue specimens were examined by real-time polymerase chain reaction. miRNA expression levels were also correlated with commonly used clinicopath-ologic features of CRC. Results: Expression levels of analyzed miRNAs significantly differed among tumors and adjacent non-tumor tissues: miR-21 (p = 0.0001) and miR-31 (p = 0.0006) were upregulated, and miR-143 (p = 0.011) and miR-145 (p = 0.003) were downregulated in tumors. For the first time, a high expression of miR-21 was associated with lymph node positivity (p = 0.025) and the development of distant metastases (p = 0.009) in CRC patients. Thus, expression of miR-21 correlated with CRC clinical stage (p = 0.032). Furthermore, tumors >50 mm in maximal tumor diameter were characterized by lower expression of miR-143 (p = 0.006) and miR-145 (p = 0.003). We found no correlation between analyzed miRNAs and serum levels of carcinoembryonic antigen. Conclusion: Our results suggest possible roles of miR-21, miR-31, miR-143 and miR-145 in CRC.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info